Insider Trading March 3, 2026

Henry Schein Chief Executive Reports $3.56M in Share Sales; Filing Shows Multiple Disposals

Insider transactions disclosed in SEC Form 4 coincide with recent quarterly outperformance and a third-party valuation note

By Jordan Park HSIC
Henry Schein Chief Executive Reports $3.56M in Share Sales; Filing Shows Multiple Disposals
HSIC

Henry Schein Chairman and CEO Stanley M. Bergman disclosed multiple share disposals in early 2026, including two transactions on March 2 totaling $3.56 million. The filings also show earlier February activity to cover tax obligations and a separate entry listing 48,531 shares at a zero-dollar disposition. The stock trades near $81.37 with a market capitalization of $9.33 billion. External research cited in reports describes the shares as overvalued relative to Fair Value, while the company recently reported fourth-quarter 2025 results that beat consensus on both earnings and revenue.

Key Points

  • Stanley M. Bergman sold 23,858 shares and 19,954 shares on March 2, 2026, for a combined total of $3.56 million at a weighted average price of $81.31 (range $81.28 to $81.38).
  • On February 27, Bergman disposed of 7,349 shares at $82.39 to cover tax obligations, totaling $605,484; the filings also show a separate disposal of 48,531 shares recorded at $0.00 with no additional context provided.
  • Henry Schein reported fourth-quarter 2025 results that beat expectations: EPS of $1.34 versus a $1.30 forecast and revenue of $3.4 billion versus an expected $3.34 billion, with investors responding positively.

Henry Schein (NASDAQ:HSIC) reported a series of insider stock dispositions by Chairman and Chief Executive Officer Stanley M. Bergman in filings submitted to the Securities and Exchange Commission.

According to a Form 4 disclosure, Bergman executed two sales on March 2, 2026, disposing of 23,858 shares and 19,954 shares. The combined proceeds from those transactions totaled $3.56 million. The sales were carried out at a weighted average price of $81.31 per share, with individual execution prices in the narrow band from $81.28 to $81.38.

The company’s common stock is quoted at $81.37 at the time of reporting, and the market capitalization stands at $9.33 billion.

The Form 4 filing also records activity from February 27, when Bergman relinquished 7,349 shares specifically to satisfy tax obligations. That disposal occurred at a price of $82.39 per share and generated $605,484 in value.

Separately, the filings include an entry showing the disposal of 48,531 shares listed with a transaction price of $0.00. The filing records the disposition but does not provide additional context about that zero-dollar figure.

Independent analysis referenced in related reporting flags the stock as currently overvalued versus its Fair Value. That same analysis notes that users can access additional tips for HSIC and a broader Pro Research Report that covers more than 1,400 U.S. equities. Those research notes are cited in connection with valuation commentary and further company coverage.

These insider transactions arrive against a backdrop of recent financial results in which Henry Schein topped expectations for the fourth quarter of 2025. Reported diluted earnings per share were $1.34, above the consensus forecast of $1.30. Revenue for the quarter reached $3.4 billion, ahead of the $3.34 billion estimate. The company’s reported results and management commentary during the earnings call are described as offering insight into strategic initiatives and the outlook.

Market participants responded positively to the quarterly results, according to reporting on investor reaction. Analysts continue to track the company’s performance and financial condition, with the recent disclosures and earnings report forming part of a series of updates on Henry Schein.


Notes on the filings and reporting

The documented facts are limited to the amounts, prices, dates and the notations included in the Form 4 filing. The filings list specific share counts and prices for the transactions described above; they do not attach explanatory commentary beyond the standard regulatory disclosure fields.

Risks

  • Insider selling can influence market perception of company prospects, which may affect investor sentiment in the healthcare services sector and broader markets.
  • Independent analysis cited in reporting indicates the stock is overvalued relative to its Fair Value, raising valuation-related uncertainty for shareholders and potential buyers.
  • The Form 4 lists a disposal of 48,531 shares at $0.00 without explanatory detail in the filing, creating an information gap about that specific transaction.

More from Insider Trading

Juniper Investment trims stake in Lincoln Educational with $5.35M sale Mar 3, 2026 Standex Director Disposes of Small Stake; Company Posts Quarterly Beat Mar 3, 2026 InterDigital CLO Disposes of 467 Shares as Company Posts Strong Results and Pursues Patent Actions Mar 3, 2026 Eos Energy CEO Buys $345,000 of Stock as Company Faces Earnings Miss and Analyst Downgrade Mar 3, 2026 NeuroOne CBO Purchases $670,400 of NMTC Stock, Adds Long-Dated Options Mar 3, 2026